Daxor's Precision Pivot: How a New Device and Strategic Shift Could Reshape Critical Care

OAK RIDGE, TN – March 03, 2026 – Daxor Corporation (Nasdaq: DXR) has signaled a profound transformation, evolving from its hybrid investment roots into a focused, high-growth medical technology company. In a detailed corporate update, CEO and President Michael Feldschuh outlined a landmark 2025, marked by robust financial performance, expanding market adoption, and the pivotal FDA clearance of a next-generation blood volume analyzer. The company is shedding its old structure to concentrate all its resources on solving what it calls healthcare’s "multi-billion-dollar silent crisis": the inability to precisely measure a patient's blood volume.

This strategic pivot is underpinned by a 45 percent surge in its operating division's revenues and a new, portable device developed with the U.S. Department of Defense, positioning Daxor to aggressively tackle inaccuracies in fluid management for conditions like heart failure and sepsis.

From Fund to Future: A Full Pivot to MedTech

Daxor has initiated a fundamental change in its corporate identity. On February 10, 2026, the company announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940 to the Securities Exchange Act of 1934. This move, expected to be completed by the second quarter of 2026, is more than a bureaucratic shift; it represents a complete alignment of the company's regulatory profile with its operational reality.

This transition follows the decisive action in December 2025 to sell all remaining positions in its investment portfolio. For years, the firm balanced its medical device operations with investment activities. Now, 100% of its time and resources are dedicated to the growth of its primary business: Blood Volume Analysis (BVA).

According to CEO Michael Feldschuh's shareholder letter, this change is a "profound financial validation" of its focused growth strategy. Reporting under the Exchange Act will require the company to provide standardized Generally Accepted Accounting Principles (GAAP) metrics, making its financial performance directly comparable to other publicly traded medical diagnostic companies. This is expected to simplify financial disclosures, improve transparency, and attract deeper interest from institutional investors and analysts who may have been deterred by the complexities of its previous structure.

Financial Fortitude Fuels Commercial Expansion

The strategic realignment is backed by a year of impressive financial and operational growth. For the year ending December 31, 2025, Daxor's net assets swelled by over $10 million to $45,887,266. This boosted its Net Asset Value to $9.07 per share, a significant increase from $7.25 per share at the end of 2024.

The company’s operating division, the core of its future, demonstrated remarkable progress. It reported a 45 percent year-over-year increase in unaudited revenues, driven by sales of its single-use BVA diagnostic kits and revenue from military contracts. Even as it invested heavily in research, development, and the expansion of its commercial sales teams, the division dramatically narrowed its operating loss to just $268,598 for 2025, a stark improvement from the $1,614,545 loss recorded in 2024. This demonstrates substantial progress toward operational break-even performance.

To further accelerate its momentum, Daxor fortified its balance sheet after the fiscal year's close. In January 2026, the company successfully closed a $9 million registered direct offering, selling shares at $11.75 each. The infusion of approximately $8.14 million in net proceeds provides critical working capital to ramp up production of its new analyzer and expand its market footprint.

A Game-Changing Device for Point-of-Care Diagnostics

The most significant catalyst for Daxor's growth was the FDA 510(k) clearance received in August 2025 for its next-generation Blood Volume Analyzer. Developed under a contract with the U.S. Department of Defense, the new system is a leap forward in diagnostic technology.

Weighing just seven pounds, the compact and portable device is designed for versatility, allowing it to be easily moved between hospital departments or even used in field settings. Critically, it delivers results three times faster than the company's previous BVA-100 system while maintaining the same laboratory-grade diagnostic precision. This combination of speed, portability, and accuracy empowers clinicians to make rapid, informed decisions about fluid management at the point of care.

The market has responded enthusiastically to this innovation. Daxor is expanding its commercial team and leveraging a dual-solution strategy to drive adoption. This includes placing the new on-site analyzers for immediate assessments and offering its CLIA-certified ezBVA Lab Service, which provides results with a 24-hour turnaround. In late 2025, the company announced accelerated market adoption with new contracts at an Upper Midwest Integrated Health System, an Ohio Academic Medical Center, and a Southwest Cardiology Group Practice, adding to earlier expansions in Kentucky, Arkansas, Philadelphia, and Florida.

Mounting Clinical Evidence in Critical Care

Daxor's commercial and strategic momentum is built on a foundation of compelling clinical evidence. The company’s BVA technology directly addresses the widespread problem of fluid mismanagement, where clinicians often rely on imprecise traditional assessments to guide treatment.

A landmark pilot study published in the Journal of Critical Care in September 2025 underscored this challenge. The study, co-authored by leading intensive care experts, found that clinical assessments were frequently wrong; 48% of COVID-19 patients deemed to have excess fluid (hypervolemic) were, in fact, fluid-depleted (hypovolemic) when measured objectively with BVA. Such misdiagnoses can lead to insufficient fluid administration or dangerous fluid overload, complicating patient recovery in the ICU.

Further validation came from the world of cardiology. New research presented at the American College of Cardiology's 2025 conference (ACC25) revealed that heart failure patients whose blood volume was optimized to a normal state (euvolemia), as identified by Daxor's BVA, experienced 2.61 times better survival. This finding highlights the life-saving potential of accurate blood volume management in one of healthcare's most challenging and costly conditions. Adding to the body of evidence, a significant study from Duke University on the utility of Blood Volume Analysis in heart failure was published in the American Heart Journal in May 2025, further solidifying the technology's scientific credibility.

With a streamlined corporate structure, a fortified balance sheet, a groundbreaking new product, and a growing mountain of clinical proof, Daxor is poised to advance its mission of replacing clinical guesswork with precision measurement. The company's focused strategy aims to establish its BVA technology as an indispensable tool in value-based healthcare, improving patient outcomes while delivering significant efficiencies for hospitals and health systems.